35 research outputs found
Advanced Active Output Filter for Low Acoustic Noise Adjustable Speed Drive (ASD) System
In recent years, the acoustic noise emitted by electric motors has become an important topic. Many manufactures of adjustable speed drive (ASD) make effort to reduce the acoustic noise from electric motors. And low acoustic noise motors can be widely applied in the next generation transport system such as electric shipboard, more electric aircraft and electric vehicle. Traditionally, LC passive filters can be employed to decrease acoustic noise by mitigating the pulse-width modulation (PWM) generated voltage/current harmonics in the audible noise range. However, the bulky passive filters contribute to additional volume and cannot effectively eliminate harmonics at low switching frequency.
In this thesis, an active output filter (AOF) is proposed to replace passive filters in ASD. The proposed AOF is implemented by the harmonic injection strategy, which can compensate voltage/current harmonics at the arbitrary frequency. Therefore, the acoustic noise, which partly generates from PWM inverter-fed ASD, is decreased dramatically. In addition, AOF offers a substantial volume reduction and high power efficiency by using wide-band gap devices. In this thesis, two different motor drive structures including single-phase ASD, three-phase ASD are investigated to verify the advantages of the proposed AOF
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)
Artificial Noise Aided Secure Transmission for Active RIS-Aided NOMA Networks
A secrecy rate maximization problem for active reconfigurable intelligent surface (RIS) aided non-orthogonal multiple access networks has been studied in this paper. Assuming that the perfect channel state information is available, we aim to maximize the secrecy rate while satisfying the quality of service of the legitimate users and power budget at the base station and active RIS. Additionally, artificial noise (AN) weakens the performance gain that the wireless channel’s characteristics would otherwise bring to the eavesdropper. We propose an iterative algorithm to address the non-convex nature of the objective function. Based on the penalty functions and successive convex approximation, we obtain a local-optimal solution. Simulation results show that: 1) active RIS with AN can bring higher performance gains as compared to the one with passive RIS; 2) the amplitude parameter in the reflection coefficient of active RIS is another parameter to enhance the secrecy rate
Robust beamforming design for passive RIS‐assisted NOMA systems
Abstract A transmission power minimization problem for a reconfigurable intelligent surface (RIS) aided non‐orthogonal multiple access (NOMA) network has been studied here, which has assumed the channel state information is imperfect. The channel error in this paper has been modeled as two different error models, that is, bounded error model and statistical error model. First, a two‐step algorithm is proposed to decouple the decoding order and optimization variables under bounded error model. Then, for the statistical error model, the alternating optimization method is adopted to decouple optimization variables. Finally, the performance difference is compared between the proposed beamforming scheme and the non‐RIS scheme from two key parameters, the number of reflected elements and the error factor. Simulation results verify that passive RIS has the advantage on the system performance compared with the scheme without RIS
Application of Taguchi Methods and ANOVA in Optimization of Process Parameters for Surface Roughness of Fused Silica in the Magnetorheological Finishing Processes
Surface roughness plays an important role on optical performances for optics in high-energy laser systems. In this study, optical surface of fused silica were polished by the Magnetorheological Finishing (MRF) processes. The polishing factors in term of Magnetorheological fluid (MR fluid) flow rate, polishing wheel rotational speed, electromagnet current, and polishing ribbon penetration depth, were carried out using an self-developed MRF machine to determine optimum conditions for surface roughness. The settings of the MRF processing parameters were determined by using Taguchi’s experimental design method. Taguchi’s orthogonal array, signal-to-noise (S/N) ratio and analysis of variance (ANOVA) were employed to investigate the optimal processing parameters. The experimental results indicate that surface with smaller roughness could be machined under the conditions with slower rotating speed and higher flow rate and current, and nearly independent of penetration depth
Impaired Mitophagy: A New Potential Mechanism of Human Chronic Atrial Fibrillation
Mitophagy is an autophagic response and plays essential roles in survival, development, and homeostasis of cells. It has been reported that mitophagic dysfunction is involved in several cardiovascular diseases. However, the effect of mitophagy on atrial fibrillation (AF) is still unknown. Therefore, we investigated the exact role of mitophagy in human chronic AF. Western blot was used to detect the protein abundance. The mitochondrial morphology and structure were observed by transmission electron microscopy. Immunofluorescent stainings were performed to analyze colocalization of mitochondria with autophagosomes or lysosomes. Totally, 43 patients with valvular heart disease undergoing cardiac surgery were selected, including 21 patients with chronic AF. Comparing with the sinus rhythm (SR) group, we found the size and number of mitochondria in atrial myocytes of patients with AF increased significantly. In addition, expression of LC3B II and LC3B II/LC3B I ratio was significantly decreased in the AF group. Moreover, the expression of p62 was markedly elevated in the AF group compared with that in the SR group. The results of immunofluorescence staining and western blot showed an enhanced expression of Cox IV in the AF group. Dual immunofluorescent stainings revealed that mitophagy defect in atrial myocytes of patients with AF resulted from dysfunction in the process of delivery of mitochondria into autophagosomes. For the first time, impaired mitophagy, during the phagocytosis of mitochondria, is associated with human chronic AF. Mitophagy could be a potential therapeutic target for AF
Two-Timescale Design for RIS-Aided Multicell MIMO Systems with Transceiver Hardware Impairments
This paper investigates the reconfigurable intelligent surface (RIS)-aided uplink multicell massive multiple-input multiple-output (mMIMO) communication system with transceiver hardware impairments (THWIs), and the practical and feasible two-timescale scheme is used to design the phase shifts of the RIS. We consider the Rician channel model and use maximal-ratio combining (MRC) technology to process the received signal at the base stations (BS). The expression of the uplink achievable rate is derived and analyzed. Moreover, the genetic algorithm (GA) is used to optimize the phase shifts of the RIS to maximize the data rate. Finally, the accuracy of the derived results is verified. The simulation results show that appropriately increasing the number of RIS reflecting elements can compensate for the performance loss caused by inter-cell interference and THWIs and reduce the demand for BS antennas, which can significantly reduce the hardware costs at the BS
Safety and Efficacy of High Power Shorter Duration Ablation Guided by Ablation Index or Lesion Size Index in Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis
Background. High power shorter duration (HPSD) ablation may lead to safe and rapid lesion formation. However, the optimal radio frequency power to achieve the desired ablation index (AI) or lesion size index (LSI) is insubstantial. This analysis aimed to appraise the clinical safety and efficacy of HPSD guided by AI or LSI (HPSD-AI or LSI) in patients with atrial fibrillation (AF). Methods. The Medline, PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to November 2020 were searched for studies comparing HPSD-AI or LSI and low power longer duration (LPLD) ablation. Results. Seven trials with 1013 patients were included in the analysis. The analyses verified that HPSD-AI or LSI revealed benefits of first-pass pulmonary vein isolation (PVI) (RR: 1.28; 95% CI: 1.05–1.56, P = 0.01) and acute pulmonary vein reconnection (PVR) (RR: 0.65; 95% CI: 0.48–0.88, P = 0.005) compared with LPLD. HPSD-AI or LSI showed higher freedom from atrial tachyarrhythmia (AT) (RR = 1.32, 95% CI: 1.14–1.53, P = 0.0002) in the subgroup analysis of studies with PVI ± (with or without additional ablation beyond PVI). HPSD-AI or LSI could short procedural time (WMD: −22.81; 95% CI, −35.03 to −10.60, P = 0.0003), ablation time (WMD: −10.80; 95% CI: −13.14 to −8.46, P < .00001), and fluoroscopy time (WMD: −7.71; 95% CI: −13.71 to −1.71, P = 0.01). Major complications and esophageal lesion in HPSD-AI or LSI group were no more than LDLP group (RR: 0.58; 95% CI: 0.20–1.69, P = 0.32) and (RR: 0.84; 95% CI: 0.43–1.61, P = 0.59). Conclusions. HPSD-AI or LSI was efficient for treating AF with shorting procedural, ablation, and fluoroscopy time, higher first-pass PVI, and reducing acute PVR and may increase freedom from AT for patients with additional ablation beyond PVI compared with LPLD. Moreover, complications and esophageal lesion were low and no different between two groups
Long Noncoding RNA HOTAIR Functions as a Competitive Endogenous RNA to Regulate Connexin43 Remodeling in Atrial Fibrillation by Sponging MicroRNA-613
Several studies have indicated that long noncoding RNAs (lncRNAs)-HOX transcript antisense RNA (HOTAIR) is involved in some cardiovascular diseases by regulating gene expression as a competitive endogenous RNA (ceRNA). GJA1 encoding Cx43 is one potential target gene of microRNA-613 (miR-613). Meanwhile, there is a potential target regulatory relationship between HOTAIR and miR-613. The present study is aimed at investigating whether HOTAIR functions as a ceRNA to regulate the Cx43 expression in atrial fibrillation (AF) by sponging miR-613. The expressions of HOTAIR, miR-613, and Cx43 were detected in the right atrial appendages of 45 patients with heart valve disease, including 23 patients with chronic AF. The HOTAIR overexpressed and underexpressed HL-1 cell model were constructed to confirm the effect of HOTAIR on Cx43. Then, the Cx43 expression was detected to testify the interplay between HOTAIR and miR-613 after cotransfecting HOTAIR and miR-613. Furthermore, luciferase assays were performed to verify that HOTAIR could regulate Cx43 remolding as a ceRNA by sponging miR-613. The expression of HOTAIR and Cx43 was significantly downregulated in chronic AF group. HOTAIR regulated positively the Cx43 expression in HL-1 cells. The upregulated effect of HOTAIR on the Cx43 expression could be remarkably attenuated by miR-613. Moreover, the inhibitory effect of miR-613 on the Cx43 expression could be obviously mitigated by HOTAIR. At last, luciferase assays confirmed HOTAIR functioned as a ceRNA in the Cx43 expression by sponging miR-613. Our study suggests that HOTAIR, functioning as a ceRNA by sponging miR-613, is an important contributor to Cx43 remolding in AF
Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis.
BACKGROUND:Acute coronary syndrome (ACS) is an important disease threatening human life and health. Many studies have shown that the loading dose of atorvastatin can significantly improve the prognosis of patients with ACS, and reduce the mortality. However, this conclusion is not consistent. Thus, we aimed to evaluate the effect of high-dose rosuvastatin loading before percutaneous coronary intervention (PCI) in Chinese patients with ACS using a meta-analysis based on a systematic review of published articles. METHODS:We systematically reviewed published studies, evaluating the effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with ACS. The retrieval time is limited from inception to 2 November 2016, and the retrieved databases included PubMed, Embase, the Cochrane Library, Web of Science, CBM, CNKI, the VIP database and the Wang Fang database. Two researchers independently assessed the quality of the included studies and then extracted the data. Stata 11.0 was used for data analysis. RESULTS:In total, 11 articles, which included 802 patients, were included in our meta-analysis. Among these patients, 398 patients were in the high-dose group (20 mg/day) and 404 patients were in the conventional dose group (10 mg/day). Meta-analysis results showed that compared with the conventional dose group: 1) The loading dose of rosuvastatin can significantly reduce the hs-CRP level after PCI, including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000), 48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11, P = 0.006), and four weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000). 2) The loading dose of rosuvastatin can significantly reduce the levels of LDL-C and cTnT, including the level of LDL-C at 30 d after PCI (SMD = -0.89, 95%CI -1.10 ~ -0.69, P = 0.000), and the level of cTnT at 24 h after PCI (SMD = -1.93, 95%CI -2.28 ~ -1.59, P = 0.000), and increase the level of HDL-C at 48 h after PCI (SMD = 0.61, 95%CI 0.34 ~ 0.88, P = 0.000). 3) The loading dose of rosuvastatin can significantly reduce the levels of TG and TC, including the level of TG at 30 d after PCI (SMD = -0.94, 95%CI -1.17 ~ -0.71, P = 0.000), the level of TC at 48 h after PCI (SMD = -0.35, 95%CI -0.68 ~ -0.01, P = 0.043), and the level of TC at 30 d after PCI (SMD = -0.77, 95%CI -0.98 ~ -0.56, P = 0.000). CONCLUSIONS:Our systematic review and meta-analysis showed that, compared with the conventional dose, the loading dose of rosuvastatin was more beneficial to patients with ACS in China and is suitable for clinical application. Due to the limitations of the quality and quantity of included articles, this conclusion still needs to be confirmed by multicenter clinical trials